The Asian cancer biotech firm will use ACT's genomic tools to research why some patients responded unusually well to its pan-HER inhibitor.
By Turna Ray
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
Nature News writes that researchers are still wrangling over the role of the p-value.
In Nature this week: paternal age associated with de novo mutations in children, and more.